Alcon's $200M RxSight partnership aims to recapture IOL market share with adjustable presbyopic lenses. RxSight gets 30% ...
Alcon (NYSE:ALC) and RxSight (Nasdaq:RXST) announced that they entered into a non-exclusive intraocular lens (IOL) ...
Non-exclusive license agreement for the development and commercialization of novel post-operative light adjustable PCIOL technologies ...
Many innovations have come to cataract surgery in the 25 years since Barry Emara, MD, opened his clinic in southwestern Ontario, but the fundamentals of the procedure have remained the same: inserting ...
“With the full U.S. availability of TECNIS PureSee IOL, we are expanding access to an important extended depth of focus option that reflects our commitment to innovation, visual quality, and patient ...
Johnson & Johnson (NYSE: JNJ) is expanding the U.S. roll-out of its latest advancement in presbyopia-correcting intraocular lenses (PC-IOLs). TECNIS PureSee IOL is an extended depth of focus (EDOF) ...
FDA has approved Johnson & Johnson's Tecnis PureSee IOL, an extended depth of focus (EDOF) intraocular lens (IOL) intended for use in cataract surgery. The new IOL will be available to U.S. patients ...
Earnings call Alcon delivered Q4 2025 sales of $2.7B, up 7% YoY, with strong contributions from new product launches and innovation in both surgical and vision care segments. Management guided to 5-7% ...
ABSTRACT: The demand for full-range visual quality in refractive cataract surgery has driven the development of non-diffractive extended depth of focus (EDOF) intraocular lenses (IOLs). Vivity ...
ABSTRACT: The demand for full-range visual quality in refractive cataract surgery has driven the development of non-diffractive extended depth of focus (EDOF) intraocular lenses (IOLs). Vivity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results